Heart Disease Trial, Recruiting NCT06185530 Sponsor: London North West Healthcare NHS Trust Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06185530
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years old
  • People who have been referred to a rapid-access chest pain clinic and, after review, have been identified as needing further heart imaging — either a stress echocardiogram (a type of ultrasound of the heart during exercise) or a CT scan of the heart's arteries — to investigate a possible diagnosis of coronary artery disease (a condition where the arteries supplying the heart become narrowed)
  • People whose calculated risk score for coronary artery disease is 5% or higher, based on European Society of Cardiology guidelines
  • People whose risk score is below 5% but whose symptoms match what doctors call "typical" chest pain — meaning chest tightness or discomfort in the chest, neck, jaw, shoulder, or arm that occurs during physical activity and goes away with rest or a nitrate medicine (such as GTN spray) within 5 minutes
  • People who are willing and able to give their consent to take part in the study and its follow-up appointments

Who may not be able to join:

  • People who have been diagnosed with an acute coronary syndrome (a serious, sudden heart condition) that requires urgent or emergency treatment or a hospital stay
  • People with a known history of blocked heart arteries, including those who have previously had a heart attack, a stent procedure, bypass heart surgery, or a heart artery scan showing a blockage of 50% or more
  • People who have had any type of heart imaging or testing for coronary artery disease (including a coronary calcium score) within the past year
  • People with a documented allergy to iodine-based contrast dye, or a documented allergy to both types of ultrasound contrast agents used at the trial site (Luminity® and SonoVue®, or their ingredients)
  • People who are unable to undergo a CT heart scan — for example, due to kidney function below a certain level, an allergy to beta-blocker medicines, a significant lung or airways condition, or exceeding the weight limit of the CT scanner
  • People who are unable to undergo a stress echocardiogram — for example, due to a specific type of thickened heart muscle condition with significant obstruction, a severe heart valve problem, or severely uncontrolled high blood pressure (180/100mmHg or above)
  • People who are pregnant
  • People who are unable to give informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Prof Roxy Senior, LNWH Trust

Phone: 0208 869 2548

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
London North West Healthcare NHS Trust
Registry
ClinicalTrials.gov
Start date
18 September 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Detection of obstructive CAD and prevalence of MACE in enrolled participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov